Literature DB >> 25739764

Immunological mechanisms of the antitumor effects of supplemental oxygenation.

Stephen M Hatfield1, Jorgen Kjaergaard1, Dmitriy Lukashev1, Taylor H Schreiber2, Bryan Belikoff1, Robert Abbott1, Shalini Sethumadhavan1, Phaethon Philbrook1, Kami Ko1, Ryan Cannici1, Molly Thayer1, Scott Rodig3, Jeffrey L Kutok3, Edwin K Jackson4, Barry Karger5, Eckhard R Podack2, Akio Ohta1, Michail V Sitkovsky6.   

Abstract

Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-β (TGF-β), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell- and natural killer cell-dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25739764      PMCID: PMC4641038          DOI: 10.1126/scitranslmed.aaa1260

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  48 in total

1.  Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells.

Authors:  M Koshiba; H Kojima; S Huang; S Apasov; M V Sitkovsky
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

Review 2.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

3.  Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport.

Authors:  S Kobayashi; H Zimmermann; D E Millhorn
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

4.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

5.  Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression.

Authors:  J Kjaergaard; S Shu
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

6.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

7.  Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling.

Authors:  H Ooi; E Cadogan; M Sweeney; K Howell; R G O'Regan; P McLoughlin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-02       Impact factor: 4.733

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

9.  T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.

Authors:  Michail V Sitkovsky
Journal:  Trends Immunol       Date:  2009-02-07       Impact factor: 16.687

10.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.

Authors:  Oscar R Colegio; Ngoc-Quynh Chu; Alison L Szabo; Thach Chu; Anne Marie Rhebergen; Vikram Jairam; Nika Cyrus; Carolyn E Brokowski; Stephanie C Eisenbarth; Gillian M Phillips; Gary W Cline; Andrew J Phillips; Ruslan Medzhitov
Journal:  Nature       Date:  2014-07-13       Impact factor: 69.504

View more
  194 in total

1.  Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy.

Authors:  Amr Hasan; Massimiliano Mazzone
Journal:  Ann Transl Med       Date:  2015-08

2.  Can respiratory hyperoxia mitigate adenosine-driven suppression of antitumor immunity?

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Ann Transl Med       Date:  2015-11

3.  Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy.

Authors:  Robert D Leone; Maureen R Horton; Jonathan D Powell
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 4.  Role of hyperoxic treatment in cancer.

Authors:  Sei W Kim; In K Kim; Sang H Lee
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-23

Review 5.  Exercise as Adjunct Therapy in Cancer.

Authors:  Kathleen A Ashcraft; Allison Betof Warner; Lee W Jones; Mark W Dewhirst
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 6.  Mitochondrial control of immunity: beyond ATP.

Authors:  Manan M Mehta; Samuel E Weinberg; Navdeep S Chandel
Journal:  Nat Rev Immunol       Date:  2017-07-03       Impact factor: 53.106

7.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

Review 8.  Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies.

Authors:  Mark W Dewhirst; Yvonne M Mowery; James B Mitchell; Murali K Cherukuri; Timothy W Secomb
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

9.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.

Authors:  Huimin Zhang; Haiquan Lu; Lisha Xiang; John W Bullen; Chuanzhao Zhang; Debangshu Samanta; Daniele M Gilkes; Jianjun He; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-28       Impact factor: 11.205

10.  Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia.

Authors:  Nicole E Scharping; Ashley V Menk; Ryan D Whetstone; Xue Zeng; Greg M Delgoffe
Journal:  Cancer Immunol Res       Date:  2016-12-09       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.